Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Precigen, Inc. PGEN

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.7M
▲ 146.7% YoY
$-250.6M
$-89.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. In August 2025, the FDA granted full approval to our product, Papzimeos (zopapogene imadenovec-drba, PRGN-2012), for the treatment of adults with recurrent respiratory papillomatosis (RRP). We have developed a proprietary electroporation device, UltraPorator, designed to further streamline and ensure the rapid and cost-effective manufacturing of UltraCAR-T therapies. We have completed enrollment in the Phase 1b clinical trial of PRGN-3006.

Written from the business description in Precigen, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 March 2026. Every sentence was checked against that document before publication.

Growth

USD 9.7M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 9.7 · Net income -250.6
100M200M-200M-400M
201120142017202020232025
Compound annual growth
−28.9%
−21.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −21.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -1141.1% · Net ·
-1000%-2000%-3000%
201120182025
ROE
FY2025 · ROE -843.6%
-500%
201120182025
Three returns, three denominators.

Each USD of equity lost 844 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -89.8
10M20M-100M-200M
201120182025

Total assetsUSD 155.5M
EquityUSD 20.9M
CashUSD 30.2M
Gross debtUSD 93.2M
Net debtUSD 62.9M
Current ratio3.09×

Net debt stands at 301% of equity.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PGEN, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.10.20.20.20.20.10.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.2−0.4−0.1−0.1−0.1−0.1−0.1−0.1−0.1
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.4−0.0−0.1−0.1−0.1−0.1−0.1−0.1
Income tax $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.0−0.00.00.00.0
Net income $B−0.3−0.1−0.10.0−0.1−0.2−0.3−0.5−0.1−0.2−0.1−0.1−0.0−0.1−0.1
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.1−0.2−0.2−0.2−0.10.0−0.0−0.1−0.1−0.1
EPS, diluted $−1.37−0.47−0.390.14−0.47−1.02−2.09−3.93−0.98−1.58−0.76−0.83−1.40−18.77−18.92
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %−843.6−160.8−78.424.2−105.6−245.6−148.3−113.6−21.4−29.8−15.7−21.8———
Shares out B0.350.290.250.210.210.190.160.160.120.120.120.100.100.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Five checks were skipped: cost of revenue is not tagged before 2012. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inVirginia
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image